Rate versus rhythm control in the management of patients with atrial fibrillation

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 10, 2005, Pages 514-521

  Pelargonio, Gemma ^a   Prystowsky, Eric N ^b,c,d  

^a CATHOLIC UNIVERSITY   (Italy)

^b ST VINCENT HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Care Group   (United States)

Author keywords

Antiarrhythmic drugs; Arrhythmias; Atrial fibrillation; Catheter ablation; Stroke

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; FLECAINIDE; PROPAFENONE; QUINIDINE; SOTALOL; VERAPAMIL; WARFARIN;

AGE DISTRIBUTION; ANTICOAGULANT THERAPY; ARRHYTHMOGENESIS; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SEVERITY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART RHYTHM; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; STROKE; TORSADE DES POINTES; TREATMENT FAILURE;

ADRENERGIC BETA-ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CATHETER ABLATION; CLINICAL TRIALS; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; QUALITY OF LIFE;

EID: 27944453090     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0320     Document Type: Review

References (49)

1. Fuster V et al. (2001) ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary. Circulation 104: 2118-2150
2. Pappone C and Santinelli V (2004) The who, what, why and how-to guide for circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol 15: 1226-1230
3. Hocini M et al. (2004) Techniques for curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 15: 1467-1471
4. Verma A et al. (2004) Pulmonary vein antrum isolation: Intracardiac echocardiography-guided technique. J Cardiovasc Electrophysiol 15: 1335-1340
5. Madrid AH et al. (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 106: 331-336
6. Pedersen OD et al. (1999) Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100: 376-380
7. Anne W et al. (2004) Atrial fibrillation after radiofrequency ablation of atrial flutter: Preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 90: 1025-1030
8. Goldstein RN et al. (2004) A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 15: 1444-1450
9. Vos MA (2004) Atrial-specific drugs: The way to treat atrial fibrillation? J Cardiovasc Electrophysiol 15: 1451-1452
10. Wolf PA et al. (1991) Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22: 983-988
11. Hart RG et al. (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 131: 492-501
12. Flacker GC and Schutz J (2004) Why is warfarin underutilized in patients with atrial fibrillation? J Interv Card Electrophysiol 10: 21-25
13. Kowey PR et al. (2003) Overview of the management of atrial fibrillation: What is the current state of the art? J Cardiovasc Electrophysiol 14: S275-S280
14. Page RL et al. (2002) Bi-Card investigators: Biphasic versus monophasic shock waveform for conversion of atrial fibrillation. The results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol 39: 1956-1963
15. Alboni P et al. (2004) Outpatient treatment of recent onset atrial fibrillation with the "pill in the pocket" approach. N Engl J Med 351: 2384-2391
16. Boriani G et al. (2004) Pharmacological cardioversion of atrial fibrillation. Drugs 64: 2741-2762
17. Prystowsky EN and Katz A (2002) Atrial fibrillation. In Textbook of Cardiovascular Medicine, 1403-1408 (Ed Topol EJ) Philadelphia: Lippincott-Raven
18. Prystowsky EN et al. (2003) Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J Cardiovasc Electrophysiol 14: S287-S290
19. Roy D et al. (2000) Amiodarone to prevent recurrent of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342: 913-920
20. Greenbaum RE et al. (1998) Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD (European and Australian Multicenter Evaluative Research on atrial Fibrillation Dofetilide) study. Circulation 98 (Suppl 1): 633
21. Chimienti M et al. (1996) Flecainide and Propafenone Italian Study (FAPIS) Investigators: Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol 77: 60A-65A
22. Naccarelli GV et al. (1996) Flecainide Multicenter Atrial Fibrillation Study Group: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation. Am J Cardiol 77: 53A-59A
23. Padanilam BJ and Prystowsky EN (2005) Atrial fibrillation - should ablation be first-line therapy and for whom: Antagonist position. Circulation 112: 1223-1229
24. Packer DL et al. (2003) Progress in nonpharmacologic therapy of atrial fibrillation. J Cardiovasc Electrophysiol 14: S296-S309
25. Pappone C et al. (2003) Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. J Am Coll Cardiol 42: 185-197
26. Corley SD et al. and the AFFIRM Investigators (2004) Relationship between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 109: 1509-1513
27. Hsu LF et al. (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351: 2373-2383
28. Farsh R et al. (1999) Ventricular control in chronic atrial fibrillation during daily activity and programmed atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimes. J Am Coll Cardiol 33: 304-310
29. Atwood JE et al. (1987) Effect of β-adrenergic blockade on exercise performance in patients with chronic atrial fibrillation. J Am Coll Cardiol 10: 314-320
30. Steinberg JS et al. (1987) Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol 9: 405-411
31. Lang R et al. (1983) Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 83: 491-499
32. Lang R et al. (1983) Verapamil improves exercise capacity in chronic atrial fibrillation: Double-blind crossover study. Am Heart J 105: 820-825
33. Olansky B et al. (2004) and the AFFIRM Investigators. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol 43: 1201-1208
34. Joshi AK et al. (2005) First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol 95: 878-887
35. Kay GN et al. and the APT Investigators (1998) The Ablate and Pace trial: A prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. J Interv Card Electrophysiol 2: 121-135
36. Brignole M et al. (1997) Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation. Circulation 96: 2617-2624
37. Wood MA et al. (2000) Clinical outcomes after ablation and pacing therapy for atrial fibrillation. A meta-analysis. Circulation 101: 1138-1144
38. Opolski G et al. for the Investigators of the Polish HOT CAFE Trial (2004) Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation. The results of the Polish How to Treat Chronic atrial Fibrillation (HOT CAFE) Study. CHEST 126: 476-486
39. Carlsson J et al. for the STAF Investigators (2003) Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. The strategies of treatment of atrial fibrillation (STAF). J Am Coll Cardiol 41: 1690-1696
40. Hohnloser SH et al. for the PIAF Investigators. (2000) Rhythm or rate control in atrial fibrillation - Pharmacological intervention in atrial fibrillation (PIAF): A randomized trial. Lancet 356: 1789-1794
41. Van Gelder IC et al. for the Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group (2002) A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347: 1834-1840
42. The Atrial Fibrillation Follow Up Investigation of Rhythm Management (AFFIRM) Investigators (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347: 1825-1833
43. deDenus S et al. (2005) Rate vs rhythm control in patients with atrial fibrillation. Arch Intern Med 165: 258-262
44. Steinberg JS et al. and the AFFIRM Investigators (2004) Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 109: 1973-1980
45. Hejna M et al. (1999) Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91: 22-36
46. The AFFIRM Investigators (2005) Quality of life in atrial fibrillation: the AFFIRM Study. Am Heart J 149: 112-120
47. Hagens VE et al. for the RACE Study Group (2004) Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. J Am Coll Cardiol 43: 241-247
48. Hagens VE et al. for the RACE Study Group (2004) Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation - results from the Rate Control versus Electrical Cardioversion (RACE) study. Eur Heart J 25: 1542-1549
49. Marshall AD et al. from the AFFIRM Investigators (2004) Cost-effectiveness of rhythm versus rate control for treatment of atrial fibrillation: Results from the AFFIRM study. Ann Intern Med 141: 653-661